Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy

Journal of Immunotherapy

Volumn 27, Issue 5, 2004, Pages 354-367

  Ribas, Antoni ^a,b   Glaspy, John A ^b   Lee, Yohan ^a   Dissette, Vivian B ^a   Seja, Elisabeth ^b   Vu, Huong T ^b   Tchekmedyian, N Simon ^e   Oseguera, Denise ^a   Comin Anduix, Begonya ^a   Wargo, Jennifer A ^a   Amarnani, Saral N ^a   McBride, William H ^c   Economou, James S ^a,d   Butterfield, Lisa H ^a,f  

^a Division of Surgical Oncology   (United States)

^b Divisionof Hematology Oncology Blood and Marrow Transplantation   (United States)

^c Dept of Exp Radiation Oncology ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Pacific Shores Medical Group   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; CTLA4; Dendritic cells; MART 1; Melanoma; Phase 1 phase 2 clinical trial

Indexed keywords

B7 ANTIGEN; BLOCKING ANTIBODY; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GAMMA INTERFERON; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; MELAN A; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VITILIGO;

EID: 4344714990     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200409000-00004     Document Type: Article

References (45)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
4. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9:998-1008.
5. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
6. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-251.
7. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288.
8. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17.
9. Kalinski P, Schuitemaker SH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162:3231-3236.
10. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
11. Chakraborty A, Li L, Chakraborty NG, et al. Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin Immunol. 2000;94:88-98.
12. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180:35-42.
13. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458-6462.
14. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221-253.
15. Green DR, Scott DW. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol. 1994;6:476-487.
16. Ribas A, Butterfield LH, Hu B, et al. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 2000;60:2218-2224.
17. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med. 2001;193:F41-F46.
18. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA4 blockade. Science. 1996;271:1734-1736.
19. Chambers CA, Kuhns MS, Egen JG, et al. CTLA4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594.
20. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985-988.
21. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade immunotherapy. Proc Natl Acad Sci USA. 1999;96:15074-15079.
22. McCoy KD, Hermans IF, Fraser JH, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med. 1999;189:1157-1162.
23. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712-4717.
24. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
25. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161:5607-5613.
26. Ribas A, Butterfield LH, Glaspy JA, et al. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002;2:57-78.
27. Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996;59:208-218.
28. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000;60:4485-4492.
29. Gardella S, Andrei C, Costigliolo S, et al. Secretion of bioactive interleukin-1beta by dendritic cells is modulated by interaction with antigen specific T cells. Blood. 2000;95:3809-3815.
30. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(Suppl 4):A8-A22.
31. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300-5308.
32. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
33. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 1999;38:73-78.
34. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999;5:1331-1338.
35. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
36. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83:215-222.
37. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
38. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 2001;98:8809-8814.
39. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254-4259.
40. Toungouz M, Libin M, Bulte F, et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol. 2001;69:937-943.
41. Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res. 2001;7:23-31.
42. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 1995;92:8078-8082.
43. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003;21:2342-2348.
44. Ribas A, Timmerman JM, Butterfield LH, et al. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003;24:58-61.
45. Farris AD, Keech CL, Gordon TP, et al. Epitope mimics and determinant spreading: pathways to autoimmunity. Cell Mol Life Sci. 2000;57:569-578.